Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.

Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is ...

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock ...

Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...

The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...

A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common gut bacteria can metabolize certain oral medications that target cellular ...

A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective. A new study, ...